Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, P.O. Box 370, H-1445, Budapest, Hungary.
Department of Anatomy, Histology and Embryology, Faculty of Medicine, Semmelweis University, Tűzoltó u. 58, P.O.Box 2, H-1428, Budapest, Hungary.
Brain Res Bull. 2019 Apr;147:78-85. doi: 10.1016/j.brainresbull.2019.02.001. Epub 2019 Feb 7.
Dipeptidyl-peptidase 4 (DPP4) enzyme is involved in the degradation of many biologically active peptides including opioids. Its role in pain transmission is poorly elucidated. Recently we reported on the spinal antihyperalgesic effects of DPP4 inhibitors, Ile-Pro-Ile (Diprotin A) and vildagliptin in carrageenan-evoked acute inflammatory pain in rats. The present study investigated the effects of intrathecal (it.) diprotin A and vildagliptin in Complete Freund's Adjuvant- (CFA) and formalin induced pain in rats. The former assay can model the subchronic inflammatory pain condition and the later one reflects both acute tonic and inflammatory pain conditions. The involvement of opioid receptor (OR) subtypes, Y1-, and GLP1 receptors were also investigated. In CFA pain model it. diprotin A or vildagliptin dose-dependently inhibits hyperalgesia in ipsilateral while has no effect in contralateral paws. The peak effect was achieved 30 min following drug administration which was used for further analysis. Both compounds showed naltrexone reversible antihyperalgesia. Co-administration of OR-subtype-selective antagonists with diprotin A and vildagliptin revealed involvement of μ and δ > μ opioid receptors, respectively. Co-administered Y1 but not GLP1 receptor antagonists reversed the antihyperalgesic action of both DPP4 inhibitors. In touch-hypersensitivity both compounds were ineffective. In formalin test only diprotin A showed μ and δ OR-mediated antinociception and only in the 2nd phase. This effect was Y1 or GLP-1 receptor antagonist insensitive. In conclusion, diprotin A and vildagliptin display antinociception of different mechanisms of action in subchronic inflammatory pain. Furthermore, the spinal pain relay points of inflammatory pain of acute or subchronic conditions were more effectively affected by diprotin A than vildagliptin which needs future elucidation.
二肽基肽酶 4(DPP4)酶参与多种生物活性肽的降解,包括阿片类物质。其在疼痛传递中的作用尚未阐明。最近,我们报道了 DPP4 抑制剂 Ile-Pro-Ile(Diprotin A)和维格列汀在角叉菜胶诱导的大鼠急性炎症性疼痛中的脊髓抗痛觉过敏作用。本研究探讨了鞘内(it.)Diprotin A 和维格列汀在完全弗氏佐剂(CFA)和甲醛诱导的大鼠疼痛中的作用。前者可以模拟亚慢性炎症性疼痛状态,后者反映急性紧张性和炎症性疼痛状态。还研究了阿片受体(OR)亚型、Y1-和 GLP1 受体的参与情况。在 CFA 疼痛模型中,it. Diprotin A 或维格列汀剂量依赖性地抑制同侧的痛觉过敏,而对对侧爪子没有影响。药物给药 30 分钟后达到峰值效应,用于进一步分析。两种化合物均显示纳洛酮可逆性抗痛觉过敏。与 Diprotin A 和维格列汀联合使用 OR 亚型选择性拮抗剂表明,μ和δ>μ阿片受体分别参与其中。联合使用 Y1 但不使用 GLP1 受体拮抗剂可逆转两种 DPP4 抑制剂的抗痛觉过敏作用。在触敏性方面,两种化合物均无效。在福尔马林试验中,只有 Diprotin A 显示出 μ 和 δ OR 介导的镇痛作用,且仅在第 2 期。这种作用对 Y1 或 GLP-1 受体拮抗剂不敏感。总之,Diprotin A 和维格列汀在亚慢性炎症性疼痛中表现出不同作用机制的镇痛作用。此外,与维格列汀相比,Diprotin A 更有效地影响急性或亚慢性条件下炎症性疼痛的脊髓疼痛传递点,这需要进一步阐明。